

[Go to Product page](#)

Datasheet for ABIN7200669

Recombinant anti-PDCD1 (Spartalizumab Biosimilar) antibody

Overview

Quantity:	1 mg
Target:	PDCD1 (Spartalizumab Biosimilar)
Reactivity:	Human
Host:	Mouse
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This PDCD1 (Spartalizumab Biosimilar) antibody is un-conjugated
Application:	Flow Cytometry (FACS), In vivo Studies (in vivo)

Product Details

Purpose:	Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody
Immunogen:	The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.
Isotype:	IgG4 kappa
Specificity:	The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Characteristics:	Recombinant Humanized IgG4 Monoclonal Antibody.
Purification:	Protein A affinity column
Purity:	> 95% by SDS-PAGE under reducing conditions and HPLC.
Sterility:	0.2 µm filtered

Product Details

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Target Details

Target: PDCD1 (Spartalizumab Biosimilar)

Target Type: Biosimilar

Background: Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months